Results 161 to 170 of about 1,494 (190)

Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Journal of Clinical Oncology, 2021
e19043 Background: BPDCN is rare cancer commonly involving the skin and marrow. Tagraxofusp (Tag), a CD123 targeted therapy, was the first FDA approved drug for BPDCN in 2018. CNS involvement occurs in 10-60% of patients and CNS staging and prophylactic (ppx) practices are variable.
Irl Brian Greenwell, James Davis, Hong Li, Deborah Soong, Justin Taylor, Andrew A. Lane, David Rizzieri   +6 more
openaire   +1 more source

BPDCN: state of the art

Hematology
Abstract The emergence of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as its own distinct entity within the pantheon of hematologic malignancies is due to the growing understanding of its unique multiorgan clinical presentation and characteristic skin lesions. The occurrence of BPDCN is generally heralded by a multicompartmental
openaire   +2 more sources

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Biological Therapy, 2019
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically been limited by small numbers of patients in the target population. In recent years, the development of tagraxofusp (SL-401) (ELZONRIS, Stemline Therapeutics) for the treatment of adult and pediatric BPDCN has ...
Mansour Alfayez, Marina Konopleva, Naveen Pemmaraju   +2 more
openaire   +2 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Blood, 2022
Naveen Pemmaraju, Hagop Kantarjian, Joseph D. Khoury, Nitin Jain, Muzaffar H Qazilbash, Sanam Loghavi, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Gautam Borthakur, Marina Konopleva   +12 more
openaire   +1 more source

Genetic Landscape of BPDCN Arising in CML Remission

Blood, 2022
Masataka Takeshita, Nobuyuki Kodama, Tomoko Hishima, Koji Okazaki, Akira Tanimura, Risen Hirai, Naomi Abe, Daisuke Kudo, Seishi Ogawa, Yasuhito Nannya, Akiyoshi Miwa   +10 more
openaire   +1 more source

Blastische plasmazytoide dendritische Zellneplasie (BPDCN)

2022
Dreger, Peter, Schweizerische Gesellschaft Für Hämatologie, Wörmann, Bernhard, Schweizerische Gesellschaft Für Medizinische Onkologie, Herling, Marco, Manz, Markus G., Simonitsch-Klupp, Ingrid, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Cozzio, Antonio Pius Martin, Guenova, Emmanuella, Rosenwald, Andreas, Jonak, Constanze, Oschlies, Ilske, Dippel, Edgar, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Bröckelmann, Paul Jan, Reimer, Peter   +16 more
openaire   +1 more source

AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program

Clinical Lymphoma Myeloma and Leukemia, 2023
Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato Sergi, Dickran Kazandjian, Enrico Attardi, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Maria Teresa Voso, Mariam Abramashvili, Mazin Al-Jadiry, Michalis Michael, Nare Martirosyan, Nino Totogashvili, Pavel Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Gevorg Tamamyan, Naveen Pemmaraju   +30 more
openaire   +1 more source

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2013
Blastic plasmacytoid dendritic cell neoplasm (BPDNC) is a rare tumour, which stems from plasmacytoid dendritic cells. Although the aetiology is still unclear, in the last few years various reports suggested a potential role of chromosomal aberrations in the oncogenesis.
A, Pileri, C, Delfino, V, Grandi, C, Agostinelli, S A, Pileri, N, Pimpinelli   +5 more
openaire   +1 more source

POSTER: AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program

Clinical Lymphoma Myeloma and Leukemia, 2023
Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato Sergi, Dickran Kazandjian, Enrico Attardi, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Maria Teresa Voso, Mariam Abramashvili, Mazin Al-Jadiry, Michalis Michael, Nare Martirosyan, Nino Totogashvili, Pavel Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Gevorg Tamamyan, Naveen Pemmaraju   +30 more
openaire   +1 more source

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Blood
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy arising from plasmacytoid dendritic cells. The most commonly affected sites include the skin (65%), bone marrow (51%), and blood (45%).
Ji Ma, Qiang He, Qian Wu, Lili Feng, Y. Lynn Wang, Linna Xie   +5 more
openaire   +1 more source